Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Raley

Pulmonary Disease Monroe, LA Medical Doctor

NPI 1235573361 CMS profile 1886745

309 Jackson St, Monroe, LA 71201

Open in the dashboard

General payments

$6,703

170 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Raley of Monroe, LA is reported in the CMS Open Payments database as having received $6,703 across 170 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,490 31
2024 General $1,446 22
2023 General $561 14
2022 General $2,070 41
2021 General $501 16
2020 General $192 12
2019 General $445 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Raley
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Matthew Raley were reported at $1,490. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Matthew Raley Pulmonary Disease median Middle half National median
2019 $445 $377 $109–$1,340 $163
2020 $192 $230 $56–$907 $114
2021 $501 $269 $68–$1,072 $132
2022 $2,070 $390 $100–$1,457 $149
2023 $561 $419 $114–$1,659 $160
2024 $1,446 $476 $123–$1,818 $164
2025 $1,490 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $3,457 63 payments
  2. Inari Medical, Inc. $869 5 payments
  3. Abbott Laboratories $709 14 payments
  4. Actelion Pharmaceuticals US, Inc. $254 17 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $148 10 payments
  6. AstraZeneca Pharmaceuticals LP $147 9 payments
  7. Ceribell, Inc. $117 1 payment
  8. United Therapeutics Corporation $112 2 payments
  9. Janssen Pharmaceuticals, Inc $107 7 payments
  10. LivaNova USA, Inc. $97 4 payments
  11. Other $687 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,958 167 payments
  2. Travel and Lodging $665 2 payments
  3. Education $80 1 payment
Products named General payments · program years 2019–2025
  1. Impella $2,183 38 payments
  2. CT THROMBECTOMY SYSTEM KIT $869 5 payments
  3. FLOWTRIEVER CATHETER, S $869 5 payments
  4. 2ND GEN CENTRIMAG PRIMARY CONSOLE $452 7 payments
  5. OPSUMIT $254 17 payments
  6. HeartMate 3 Left Ventricular Assist Device $150 2 payments
  7. AVYCAZ $130 8 payments
  8. SPIRIVA RESPIMAT $120 8 payments
  9. POCKET EEG DEVICE $117 1 payment
  10. TYVASO $112 2 payments
  11. Other $1,004 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$63,455

Medicare's payments for the services billed

Medicare patients

188

Average age 74

Services billed

576

88 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 68%
Heart failure 63%
Arthritis 61%
Diabetes 57%
Atrial fibrillation 52%
Chronic kidney disease 51%
COPD 51%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

170 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record